Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HPSE | Q9Y251 | 6/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | COMT | P21964 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19739152 | 0.86 | SMN1; SMN2 (0.55) | SMN1; SMN2TP53MAPTHPSEALDH1A1 | |
| SCHEMBL30045266 | 0.86 | MAPT (0.51) | SMN1; SMN2TP53MAPTHPSEALDH1A1 | |
| SCHEMBL5190823 | 0.83 | KDM4E (0.53) | SMN1; SMN2TP53MAPTHPSEALDH1A1 | |
| SCHEMBL19739335 | 0.82 | MMP2 (0.53) | SMN1; SMN2TP53MAPTALDH1A1NPC1 | |
| SCHEMBL6529336 | 0.81 | HPSE (0.73) | SMN1; SMN2HPSEALDH1A1NPC1PKM | |
| SCHEMBL30045333 | 0.80 | TP53 (0.47) | SMN1; SMN2TP53MAPTHPSEALDH1A1 | |
| SCHEMBL6528731 | 0.79 | HPSE (0.61) | HPSEALDH1A1KDM4EPOLBHPGD | |
| SCHEMBL19753933 | 0.78 | TP53 (0.61) | SMN1; SMN2TP53MAPTHPSEALDH1A1 | |
| SCHEMBL14381770 | 0.78 | COMT (0.66) | SMN1; SMN2TP53MAPTHPSENPC1 | |
| SCHEMBL3978246 | 0.77 | CYP17A1 (0.58) | SMN1; SMN2TP53ALDH1A1NPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3475284-B1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS INC (US) | 2022-11-02 | — | — | EP | disclosed |
| EP-3475284-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | Mersana Therapeutics, Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| WO-2017223275-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. (US) | 2017-12-28 | — | — | WO | disclosed |
| US-20170369453-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369453-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD79B, CLTB, FCGR3B | SMN1; SMN2 2865/4885TP53 595/4885MAPT 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.